FY2024 Earnings Forecast for Vericel Issued By HC Wainwright

Vericel Co. (NASDAQ:VCEL) – Equities research analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Vericel in a research note issued to investors on Wednesday, January 15th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn $0.16 per share for the year, down from their previous forecast of $0.21. HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Vericel’s Q4 2024 earnings at $0.33 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.00 EPS and FY2029 earnings at $2.80 EPS.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The company had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million.

A number of other equities research analysts also recently weighed in on VCEL. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $60.00 target price on shares of Vericel in a research note on Tuesday, November 19th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research report on Tuesday, December 24th. Truist Financial upped their target price on shares of Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. BTIG Research raised their price target on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Finally, Stephens reiterated an “overweight” rating and issued a $65.00 price objective on shares of Vericel in a report on Wednesday. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Vericel presently has an average rating of “Moderate Buy” and an average target price of $62.14.

Vericel Trading Down 2.1 %

Shares of VCEL opened at $56.35 on Thursday. Vericel has a 12-month low of $37.35 and a 12-month high of $61.49. The company has a market cap of $2.78 billion, a PE ratio of 939.32 and a beta of 1.72. The stock has a 50-day moving average price of $56.80 and a 200-day moving average price of $49.89.

Insider Buying and Selling at Vericel

In other news, Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $60.00, for a total transaction of $150,000.00. Following the completion of the sale, the director now owns 26,595 shares of the company’s stock, valued at approximately $1,595,700. This represents a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Mark Hopper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $58.72, for a total transaction of $587,200.00. Following the completion of the transaction, the insider now owns 58,371 shares in the company, valued at $3,427,545.12. This represents a 14.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,100 shares of company stock worth $889,872 over the last three months. Company insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On Vericel

A number of hedge funds have recently modified their holdings of the company. Park Avenue Securities LLC bought a new stake in shares of Vericel in the fourth quarter worth about $280,000. Diversified Trust Co bought a new stake in shares of Vericel in the 4th quarter worth approximately $356,000. Franklin Resources Inc. grew its position in shares of Vericel by 14.0% in the 3rd quarter. Franklin Resources Inc. now owns 33,543 shares of the biotechnology company’s stock worth $1,412,000 after buying an additional 4,117 shares during the last quarter. Synovus Financial Corp increased its stake in shares of Vericel by 38.5% during the third quarter. Synovus Financial Corp now owns 11,576 shares of the biotechnology company’s stock valued at $489,000 after buying an additional 3,219 shares during the period. Finally, Sanctuary Advisors LLC bought a new position in shares of Vericel during the third quarter valued at approximately $185,000.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.